Letters, Testimony & Comments

March 28, 2014
March 15, 2013   Ms. Marilyn Tavenner, B.S.N., M.H.A. Acting Administrator Centers for Medicare & Medicaid Services Room 445–G, Hubert H. Humphrey Building 200 Independence Avenue, SW Washington, DC 20201   Re...
March 27, 2014
February 25, 2013     Marilyn Tavenner, B.S.N., M.H.A. Administrator Centers for Medicare & Medicaid Services Room 445–G, Hubert H. Humphrey Building 200 Independence Avenue, SW Washington, DC 20201  ...
March 27, 2014
VIA ELECTRONIC SUBMISSION   March 1, 2014     Patrick Conway, M.D. Deputy Administrator for Innovation and Quality Chief Medical Officer Centers for Medicare & Medicaid Services Center for Medicare and Medicaid...
March 25, 2014
Dear Chairman Wyden and Ranking Member Hatch:   As the Senate Finance Committee begins its work on tax extenders, we encourage you to extend the suite of critical advanced biofuels tax incentives – the Second Generation Biofuel...
March 10, 2014
BIO appreciates FDA’s efforts in convening its two day public workshop on January 6-7th entitled “Complex Issues in Developing Drug and Biological Products for Rare Diseases” as required by the Food and Drug Administration Safety...
March 7, 2014
  March 7, 2014   BY ELECTRONIC DELIVERY   Marilyn B. Tavenner Administrator Centers for Medicare & Medicaid Services U.S. Department of Health and Human Services Hubert H. Humphrey Building, Room 445-G 200...
March 7, 2014
On March 7, 2014, BIO submitted comments to the U.S. Office of Personnel Management (OPM) regarding OPM’s February 4, 2014 Multi-State Plan (MSP) Program Call Letter.  BIO’s comments address the critical nature of the Affordable...
March 4, 2014
March 4, 2014 Regulatory Analysis and Development PPD, APHIS Station 3A-03.8 4700 River Road Unit 118 Riverdale, MD 20737-1238   Re: U.S. Department of Agriculture Docket No. APHIS-2013-0047   Dear Sir or Madam:...
March 4, 2014
  Dear Sir/Madam: The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Request for Nominations: Drug Products that Present Demonstrable...
February 25, 2014
Stanford McCoy Assistant U.S. Trade Representative for Intellectual Property and Innovation Office of the U.S. Trade Representative Chair of the Special 301 Committee Office of the United States Trade Representative Washington, D.C....
February 25, 2014
BIO joined with the American Pharmacists Association (APhA), Association of State and Territorial Health Officials (ASTHO), Immunization Action Coalition (IAC), Merck, and the National Association of County and City Health Officials (NACCHO) to...
February 24, 2014
Good morning. My name is Lila Feisee, Vice President of International Affairs at the Biotechnology Industry Organization (BIO).  Today, I am testifying on behalf of BIO and its 1100 members who innovate in the healthcare, agriculture,...
February 24, 2014
Dear Sir or Madam:   The Pharmaceutical Research and Manufacturers of America (PhRMA) and Biotechnology Industry Organization (BIO) are pleased to submit these comments in response to the Food and Drug Administration’s (FDA’s...
February 12, 2014
On behalf of the Biotechnology Industry Organization (BIO), I hereby submit comments on the Senate Committee on Finance staff discussion draft to reform certain energy tax provisions. BIO is the world's largest trade association representing...
February 12, 2014
The Honorable David Borden, Committee Chair The Honorable Charles Townsend, Committee Vice-Chair And the Members of the Science, Technology & Energy Committee: Chairman Borden, Vice Chairman Townsend, and Members of the Committee, the...
February 3, 2014
 Dear Sir/Madam: The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Draft Guidance for Industry on Pharmacy Compounding of Human Drug Products...
January 31, 2014
Dear Ms. Badrov:   The Biotechnology Industry Organization (BIO) and the Illinois Biotechnology Industry Organization (iBIO) appreciate this opportunity to comment on the Illinois Department of Healthcare and Family Services (the “...
January 31, 2014
Dear Ms. Gibson: To Whom It May Concern: The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Texas Health and Human Services Commission (HHSC) proposed rule regarding 340B program reimbursement (the...